Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Antonella Sistigu; Takahiro Yamazaki; Erika Vacchelli; Kariman Chaba; David Enot; Julien Adam; Ilio Vitale; Aïcha Goubar; Elisa Elena Baracco; Catarina Remédios; Laetitia Fend; Dalil Hannani; Laetitia Aymeric; Yuting Ma; Mireia Niso‐Santano; Oliver Kepp; Joachim L. Schultze; Thomas Tüting; Filippo Belardelli; Laura Bracci; Valentina La Sorsa; Giovanna Ziccheddu; Paola Sestili; Francesca Urbani; Mauro Delorenzi; Magali Lacroix‐Triki; Virginie Quidville; Rosa Conforti; Jean-Philippe Spano; Lajos Pusztai; Vichnou Poirier-Colame; Suzette Delaloge; Frédérique Penault‐Llorca; Sylvain Ladoire; Laurent Arnould; Joanna Cyrta; Marie-Charlotte Dessoliers; Alexander Eggermont; Marco E. Bianchi; Mikaël J. Pittet; Camilla Engblom; Christina Pfirschke; Xavier Préville; Gilles Uzé; Robert D. Schreiber; Melvyn T. Chow; Mark J. Smyth; Enrico Proietti; Fabrice André; Guido Guido Kroemer; Laurence Zitvogel

doi:10.1038/nm.3708

Related publications

Article2016

Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy

Heng Yang, Yuting Ma, Guo Chen, Heng Zhou, Takahiro Yamazaki, Christophe Klein, Federico Pietrocola, Erika Vacchelli, Sylvie Souquère, Allan Sauvat, Laurence Zitvogel, Oliver Kepp, Guido Guido Kroemer

Article2015

STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Guido Kroemer

Preprint2023

Data from STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Guido Kroemer

Preprint2023

Data from STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Guido Kroemer

Article2009

A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA

Myoung Kwon Choi, Zhichao Wang, Tatsuma Ban, Hideyuki Yanai, Yan Lu, Ryuji Koshiba, Yukana Nakaima, Sho Hangai, David A. Savitsky, Makoto Nakasato, Hideo Negishi, Osamu Takeuchi, Kenya Honda, Akira Shizuo, Tomohiko Tamura, Tadatsugu Taniguchi

Proceedings of the National Academy of Sciences

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Discussion(0)

Related publications

Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy

STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

Data from STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

Data from STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells

A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA